What Eiger BioPharmaceuticals, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 0 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Kayne Richard A | 10% owner | Nov 02 | Open-market buy · P | +23,398 | $0.30 | +$6.97K | 5,375,225 |
| Kayne Richard A | 10% owner | Nov 01 | Open-market buy · P | +100,000 | $0.28 | +$28K | 5,351,827 |
| Kawas Leen | 10% owner | Oct 31 | Open-market buy · P | +12,345 | $0.26 | +$3.23K | 4,391,432 |
| Kawas Leen | 10% owner | Oct 31 | Open-market buy · P | +11,987 | $0.26 | +$3.15K | 4,379,087 |
| Kayne Richard A | 10% owner | Oct 31 | Open-market buy · P | +130,509 | $0.24 | +$31.5K | 5,251,827 |
| Kayne Richard A | 10% owner | Oct 31 | Open-market buy · P | +12,345 | $0.26 | +$3.23K | 5,121,318 |
| Kayne Richard A | 10% owner | Oct 31 | Open-market buy · P | +11,987 | $0.26 | +$3.15K | 5,108,973 |
| Mayer Eldon C. Iii | Ex VP & Chief Commerc. Officer | Mar 17 | Sale for tax withholding · S | −1,875 | $1.07 | −$2.01K | 56,073 |
| Mayer Eldon C. Iii | Ex VP & Chief Commerc. Officer | Mar 17 | Sale for tax withholding · S | −2,520 | $1.07 | −$2.7K | 57,948 |
| Dietz Thomas John | Director | Jan 23 | Open-market buy · P | +50,000 | $1.43 | +$71.6K | 50,000 |
| Murray Christine | Director | Dec 29 | Open-market sale · S | −5,000 | $1.22 | −$6.1K | 11,000 |
| Dietz Thomas John | Director | Dec 22 | Open-market sale · S | −22,500 | $1.17 | −$26.3K | 21,000 |
| Glenn Jeffrey S | Director | Dec 22 | Open-market buy · P | +100,000 | $1.28 | +$128K | 182,355 |
| Apelian David | Director | Aug 16 | Disclosed 10b5-1 sale · S | −5,000 | $9.81 | −$49K | 11,000 |
| Ryali Sriram | Chief Financial Officer | Mar 14 | Sale for tax withholding · S | −2,266 | $5.60 | −$12.7K | 41,566 |
| Mayer Eldon C. Iii | Ex VP & Chief Commerc. Officer | Mar 14 | Sale for tax withholding · S | −1,657 | $5.60 | −$9.27K | 60,468 |
| Dietz Thomas John | Director | Mar 11 | Grant / award · A | +6,000 | — | — | 43,500 |
| Sachdev Amit | Director | Mar 11 | Grant / award · A | +6,000 | — | — | 16,000 |
| Mayer Eldon C. Iii | Ex VP & Chief Commerc. Officer | Mar 11 | Grant / award · A | +16,000 | — | — | 62,125 |
| Cory David A | President and CEO | Mar 11 | Grant / award · A | +47,000 | — | — | 169,183 |
Loading...
